Viral-toxin interactions and Parkinson’s disease: poly(I:C) priming enhanced the neurodegenerative effects of paraquat

Journal of Neuroinflammation

Shawn Hayley¹  Melanie Clarke¹  Kerry Moloney¹  Eric Nelson¹  Anusha Gandhi¹  Emily N Mangano¹  Jessica Bobyn¹ 

[1] Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, ON, K1S 5B6, Canada

关键词: Viral;    Pesticide;    Cytokine;    Microglia;    Neurodegeneration;    Neuroinflammation;   

Others  :  1212632
DOI  :  10.1186/1742-2094-9-86

 received in 2011-12-06, accepted in 2012-03-20,  发布年份 2012

【 授权许可】

   
2012 Bobyn et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lev N, Melamed E, Offen D: Apoptosis and Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:245-250.
• [2]McCoy MK, Cookson MR: Mitochondrial quality control and dynamics in Parkinson’s disease. Antioxid Redox Signalin press
• [3]McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P: Failure of the ubiquitin-proteosome system in Parkinson’s disease. Nat Rev Neurosci 2001, 2:589-594.
• [4]Nagatsu T, Mogi M, Ichinose H, Togari A: Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm Suppl 2000, 60:277-290.
• [5]Olanow CW, Tatton WG: Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 1999, 22:123-144.
• [6]McGeer PL, McGeer EG: Glial reactions in Parkinson’s disease. Mov Disord 2008, 23:474-483.
• [7]Nagatsu T, Sawada M: Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 2005, 11:999-1016.
• [8]Tufekci KU, Genc S, Genc K: The endotoxin-induced neuroinflammation model of Parkinson’s disease. Parkinsons Dis 2011, 2011:487450.
• [9]Ling Z, Zhu Y, Tong C, Snyder JA, Lipton JW, Carvey PM: Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol 2006, 199:499-512.
• [10]Tansey MG, McCoy MK, Frank-Cannon TC: Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007, 208:1-25.
• [11]Hawkes CH, Del Tredici K, Braak H: Parkinson’s disease: the dual hit theory revisited. Ann N Y Acad Sci 2009, 1170:615-622.
• [12]Mangano E, Hayley S: Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: neuroimmune sensitization of neurodegeneration. Neurobiol Aging 2009, l30:1361-1378.
• [13]Sulzer D: Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci 2007, 30:244-250.
• [14]Ling Z, Chang QA, Tong CW, Leurgans SE, Lipton JW, Carvey PM: Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally. Exp Neurol 2004, 190:373-383.
• [15]Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV: Toll-like receptors in neurodegeneration. Brain Res Rev 2009, 59:278-292.
• [16]Olson JK, Miller SD: Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004, 173:3916-3924.
• [17]Trudler D, Farfara D, Frenkel D: Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic disease: towards future therapeutic application. Mediators Inflamm 2010, 2010:497987.
• [18]Hamanaka J, Hara H: Involvement of Toll-Like Receptors in Ischemia-Induced Neuronal Damage. Cent Nerv Syst Agents Med Chem 2009. in press
• [19]Landreth GE, Reed-Geaghan EG: Toll-like receptors in Alzheimer’s disease. Curr Top Microbiol Immunol 2009, 336:137-153.
• [20]Racke MK, Drew PD: Toll-like receptors in multiple sclerosis. Curr Top Microbiol Immunol 2009, 336:155-168.
• [21]Casals J, Elizan TS, Yahr MD: Post-encephalitic parkinsonism-a review. J Neural Transm 1998, 105:645-676.
• [22]Dickman MS: Von economo encephalitis. Arch Neurol 2001, 58:1696-1698.
• [23]Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, Smeyne RJ: Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A 2009, 106:14063-14068.
• [24]Ravenholt RT, Foege WH: 1918 influenza, encephalitis lethargic, parkinsonism. Lancet 1982, 2:860-864.
• [25]Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O: The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci 2010, 30:16091-16101.
• [26]Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ: Paraquat elicited neurobehavioural syndrome caused by dopaminergic neuron loss. Brain Res 1999, 823:1-10.
• [27]Mangano EN, Peters S, Litteljohn D, So R, Bethune C, Bobyn J, Clarke M, Hayley S: Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson’s disease. Neurobiol Dis 2011, 43:99-112.
• [28]Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, Grimm E, Callaghan SM, Slack RS, Melloni E, Przedborksi S, Robertson GS, Anisman H, Merali Z, Park DS: Inhibition of calpains prevents neuronal and behavioural deficits in an MPTP mouse model of Parkinson’s disease. J Neurosci 2003, 23:4081-4091.
• [29]Litteljohn D, Mangano E, Hayley S: Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur J Neurosci 2008, 28:707-716.
• [30]Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK: MPTP susceptibility in the mouse: behavioural, neurochemical and histological analysis of gender and strain differences. Behav Genet 2000, 30:171-182.
• [31]Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 2000, 3:1301-1306.
• [32]Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B: Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009, 169:919-926.
• [33]Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, Shepherd S: Pesticide/environmental exposures and Parkinson’s disease in East Texas. J Agromedicine 2008, 13:37-48.
• [34]Hatcher JM, Pennell KD, Miller GW: Parkinson’s disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 2008, 29:322-329.
• [35]Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D: Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 2005, 113:1230-1233.
• [36]Takahashi M, Yamada T: Viral etiology for Parkinson’s disease-a possible role of influenza a virus infection. Jpn J Infect Dis 1999, 52:89-98.
• [37]Blandini F, Armentero MT, Martignoni E: The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 2008, 14(Suppl 2):124-129.
• [38]Cicchetti F, Drouin-Ouellet J, Gross RE: Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 2009, 30:475-483.
• [39]Erazi H, Ahboucha S, Gamrani H: Chronic exposure to aluminum reduces tyrosine hydroxylase expression in the substantia nigra and locomotor performance in rats. Neurosci Lett 2011, 487:8-11.
• [40]Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.
• [41]McGeer PL, McGeer EG: Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 2004, 10(Suppl 1):3-7.
• [42]Barcia C, Ros CM, Annese V, Gomez A, Ros-Bernal F, Aguado-Yera D, Martinez-Pagan ME, de Pablos V, Fernandez-Villalba E, Herrero MT: IFN-γ signalling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson’s disease. Cell Death Dis 2011, 2:e142.
• [43]Mangano EN, Litteljohn D, So R, Nelson E, Peters S, Bethune C, Bobyn J, Hayley S: Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. Neurobiol Aging 2009. in press
• [44]Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS: Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 2007, 27:3328-3337.
• [45]Doyle SE, O’Connell R, Vaidya SA, Chow EK, Yee K, Cheng G: Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. J Immunol 2003, 170:3565-3571.
• [46]Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP: TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 2005, 175:4320-4330.
• [47]Jenner P, Olanow CW: Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 1996, 47(Suppl 3):161-170.
• [48]Gao HM, Liu B, Hong JS: Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2003, 23:6181-6187.
• [49]Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborksi S: NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci U S A 2003, 100:6145-6150.
• [50]Anrather J, Racchumi G, Iadecola C: NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 2006, 281:5657-5667.
• [51]Babior BM: NADPH oxidase: an update. Blood 1999, 93:1464-1476.
• [52]Gupta SP, Patel S, Yadav S, Singh AK, Singh S, Singh MP: Involvement of nitric oxide in maneb- and paraquat-induced Parkinson’s disease phenotype in mouse: is there any link with lipid peroxidation? Neurochem Res 2010, 35:1206-1213.
• [53]Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH: Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson’s disease. J Neurosci 2001, 12:8447-8455.
• [54]Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S: Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
• [55]McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA: Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002, 10:119-127.
• [56]Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, Wu GC, Cao XD, Hong JS: Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000, 295:125-132.
• [57]Cicchetti F, Lapointe N, Roberge-Tremblay A, Saint-Pierre M, Jimenez L, Ficke BW, Gross RE: Systemic exposure to paraquat and maneb models early Parkinson’s disease in young adult rats. Neurobiol Dis 2005, 20:360-371.
• [58]Goldman SA: Adult neurogenesis: from canaries to the clinic. J Neurobiol 1998, 36:267-286.
• [59]Im SH, Yu JH, Park ES, Lee JE, Kim HO, Park KI, Kim GW, Park CI, Cho SR: Induction of striatal neurogenesis enhances functional recovery in an adult animal model of neonatal hypoxic-ischemic brain injury. Neuroscience 2010, 169:259-268.
• [60]Kreuzberg M, Kanov E, Timofeev O, Schwaninger M, Monyer H, Khodosevich K: Increased subventricular zone-derived cortical neurogenesis after ischemic lesion. Exp Neurol 2010, 226:90-99.
• [61]Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM: Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol 2002, 52:802-813.
• [62]Peng J, Xie L, Jin K, Greenberg DA, Andersen JK: Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Neuroscience 2008, 153:664-670.
• [63]Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW: Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 2005, 88:193-201.